Products & ReviewLife Sciences
Infliximab Total Anti-drug ELISA (IDKmonitor®)
Determination of total anti-infliximab antibodies Infliximab is a recombinant protein used to treat inflammatory bowel disease (IBD). The protein can induce humoral immune responses and lead to anti-drug antibody formation, a major cause of loss of drug response. IDKmonitor Infliximab Total Anti-drug ELISA kit is a ‘drug tolerant’ assay that enables the detection of anti-drug antibodies in the presence of circulating drug.
Request Pricing
Receive your quote directly from the manufacturer.
The assay is widely available throughout the UK and Ireland to both routine clinical laboratories as well as for research applications.
This kit is supported by UK publications and evidence base.
Key advantages
- Supports the investigation of primary non-response and loss of response to infliximab
- Highly sensitive drug tolerant assay that detects total anti-infliximab antibodies (those free and bound to infliximab)
- May help to predict long term outcome of disease
- Identifies patients with low-titre anti-infliximab antibodies
- Applicable to both gastroenterology and rheumatology
- Automatable on ELISA automates (e.g. Dynex DS2)
Specifications
- ELISA
- 45 tests
- Storage: 2-8 °C
- Blood sample
